{"id":1149,"date":"2026-08-24T10:00:54","date_gmt":"2026-08-24T02:00:54","guid":{"rendered":"https:\/\/onemoremoney.com\/onemorestock\/moderna-mrna-cancer-vaccine-phase-3\/"},"modified":"2026-08-24T10:00:54","modified_gmt":"2026-08-24T02:00:54","slug":"moderna-mrna-cancer-vaccine-phase-3","status":"publish","type":"post","link":"https:\/\/onemoremoney.com\/onemorestock\/moderna-mrna-cancer-vaccine-phase-3\/","title":{"rendered":"Moderna Stock (MRNA): Inside the Phase 3 Cancer Vaccine Win"},"content":{"rendered":"\n

Moderna Stock (MRNA): Inside the Phase 3 Cancer Vaccine Win<\/h1>\n\n\n\n

1. Introduction<\/h2>\n\n\n\n

On 19 August 2026, Moderna closed up 176.97% at $174.38. It was the best day in the company’s history and the largest single-session gain in the S&P 500 that day, adding roughly $45 billion of market value in a few hours.<\/p>\n\n\n\n

The catalyst was a single sentence of clinical news. Moderna and Merck announced that INTerpath-001, the Phase 3 trial of their individualised mRNA cancer therapy given alongside Keytruda, met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival in resected melanoma.<\/p>\n\n\n\n

That is the first time a personalised neoantigen therapy has succeeded in a randomised Phase 3 trial, and the first time any mRNA cancer therapy has. For a company the market had spent three years treating as a post-pandemic melting ice cube, it is a genuine change in the investment case.<\/p>\n\n\n\n

It is also, so far, a topline announcement. The hazard ratios have not been published. Overall survival is still being followed. Moderna is still losing more than $700 million a quarter. This article works through what changed, what it is plausibly worth, and what still has to go right.<\/p>\n\n\n\n

2. Key Financial Metrics<\/h2>\n\n\n\n
Metric<\/th>Value<\/th><\/tr><\/thead>
Share price (21 Aug 2026)<\/td>$145.84<\/td><\/tr>
Market capitalisation<\/td>About $57.9 billion<\/td><\/tr>
52 week range<\/td>$22.28 to $176.66<\/td><\/tr>
Shares outstanding<\/td>399.24 million<\/td><\/tr>
Q2 2026 revenue<\/td>$145 million, up 2% YoY<\/td><\/tr>
Q2 2026 GAAP net loss<\/td>$782 million<\/td><\/tr>
Q2 2026 diluted EPS<\/td>-$1.97<\/td><\/tr>
Cash and investments (30 Jun 2026)<\/td>$6.9 billion<\/td><\/tr>
FY2026 revenue guidance<\/td>Up to 10% growth<\/td><\/tr>
FY2026 year end cash guidance<\/td>$4.7 billion to $5.2 billion<\/td><\/tr>
Short interest (21 Aug 2026)<\/td>13.5% of free float<\/td><\/tr>
All time high (9 Aug 2021)<\/td>$497.49<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Data as of 21 August 2026.<\/em><\/p>\n\n\n\n

3. What Moderna Is Today<\/h2>\n\n\n\n

Moderna is a messenger RNA platform company. Its commercial business is respiratory vaccines, principally COVID-19 and RSV, and that business has been shrinking for four consecutive years as pandemic-era demand normalised.<\/p>\n\n\n\n

The scale of the de-rating is easy to understand and easy to forget. Moderna traded at an intraday high of $497.49 in August 2021. By November 2025 it had reached a 52-week low of $22.28. Before the melanoma readout it was changing hands near $63.<\/p>\n\n\n\n

What survived that collapse is the platform. Moderna reports 44 development candidates, 37 of which have entered clinical trials, including three cancer vaccine programmes. The bear argument for the past three years was that none of this pipeline was worth much because none of it had produced a randomised late-stage win. That specific argument is now harder to make.<\/p>\n\n\n\n

The market had positioned accordingly. Short interest sat at 13.5% of the free float going into the readout, one of the heaviest short positions in any US large-cap. Bloomberg reported that short sellers took roughly $5.5 billion in mark-to-market losses on the day. Some of the 177% move was fundamental repricing and some of it was forced covering. Both are real, but only one of them repeats.<\/p>\n\n\n\n

4. What Actually Happened in INTerpath-001<\/h2>\n\n\n\n

INTerpath-001 is a Phase 3, randomised, double-blind study run by Merck in patients with completely resected high-risk stage II to IV melanoma. Its ClinicalTrials.gov registration<\/a> records enrolment of 1,089 participants. Roughly two-thirds were randomised to intismeran autogene, previously known as V940 or mRNA-4157, plus Merck’s Keytruda. The remainder received placebo plus Keytruda.<\/p>\n\n\n\n

At a prespecified interim analysis, independent monitors found statistically significant and clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival for the combination. No new safety signals emerged.<\/p>\n\n\n\n

Three details matter more than the headline:<\/p>\n\n\n\n